Announcements Trials
Browse Landscape

Phase

Phase 1 5Phase 1/2 3Phase 2 2Phase NA 1

Status

Withdrawn 1Completed 1

Sponsor Class

OTHER 2NETWORK 1

Study Type

Interventional 2

Sponsor

Cancer Type

CNS 2Sarcoma 1Endocrine 1

Conditions

Prolactinoma 1Pituitary Neoplasms 1Growth Hormone-Secreting Pituitary Adenoma 1Gliosarcoma 1Glioblastoma 1Central Nervous System Neoplasms 1Adenoma, Chromophobe 1Adenoma, Basophil 1Adenoma, Acidophil 1

Interventions

Cisplatin 1041Cyclophosphamide 973Carboplatin 954Radiotherapy 893Bevacizumab 847Gemcitabine 817pembrolizumab 759Paclitaxel 738Docetaxel 734Oxaliplatin 706Capecitabine 649Fluorouracil 564Rituximab 559Nivolumab 506Dexamethasone 487Etoposide 468Doxorubicin 458Irinotecan 442Drug Therapy 402Leucovorin 377Cytarabine 342Cetuximab 340Lenalidomide 326Trastuzumab 323Pemetrexed 315durvalumab 295Filgrastim 287Magnetic Resonance Spectroscopy 278Temozolomide 275Prednisone 274

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 2 × OTHER × DNA Methylation × Clear all
NCT01149850 2024-09-19

Bevacizumab and Temozolomide in Treating Older Patients With Newly-Diagnosed Glioblastoma Multiforme or Gliosarcoma

Jonsson Comprehensive Cancer Center

Phase 2 Completed
50 enrolled
CNSSarcoma

Glioblastoma, Gliosarcoma

NCT00601289 2020-07-31

Temozolomide in Treating Patients With Invasive Pituitary Tumors

Jonsson Comprehensive Cancer Center

Phase 2 Withdrawn
CNSEndocrine

Adenoma, Basophil, Adenoma, Chromophobe, Adenoma, Acidophil, Pituitary Neoplasms, Prolactinoma, Central Nervous System Neoplasms, Growth Hormone-Secreting Pituitary Adenoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡